The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Distribution and Administration of Potassium Iodide in the Event of a Nuclear Incident
pollution. He has a 10-year history of service to the Institute of Medicine (IOM), and was recognized for his contributions by his appointment as a National Academies fellow. He is a member of the IOM Board on Health Promotion and Disease Prevention, is the board liaison to the Committee on Poison Control, and is the former chair of the IOM Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides.
David V. Becker, MD, is professor of radiology and medicine at Weill-Cornell Medical College in the Department of Radiology in the Division of Nuclear Medicine at New York-Presbyterian Hospital in New York City. Dr. Becker’s clinical and research interests are primarily in thyroid physiology, radiation effects on the thyroid, and the management of clinical thyroid disease, with a particular focus on the pathophysiology of thyroid disease in humans and animals with emphasis on iodine and thyroid hormone metabolism in a variety of clinical disorders. His major clinical activities are related to the use of radioiodine for the management of hyperthyroidism and thyroid cancer. Dr. Becker has been president of the American Thyroid Association, and is a fellow of the American College of Physicians, the American College of Endocrinology, and the New York Academy of Medicine. In recognition of his clinical activities in patient care, he has been cited in the last three editions of the Best Doctors in the United States in the areas of both nuclear medicine and thyroid disease. Since 1983, he has participated in the National Cancer Institute’s I-131 Risk Assessment Study Group, which was mandated by Congress to determine the risk factors in radioiodine use. That group has evolved into the present Chornobyl Fallout Joint Study Group, which Dr. Becker chaired. He participates in a number of consultative and policy making committees. Dr. Becker was the founding member of the executive committee of a multicenter US Public Health Service study of 36,000 hyperthyroid patients, of whom 23,000 received radioiodine treatment. Initiated in 1960, that follow-up study represents the largest radioiodine-treated hyperthyroid population. After an internship in internal medicine, Dr. Becker was a fellow in the Biophysics Department of the Sloan-Kettering Institute from 1950 to 1952. Later, he entered the US Army, where he